Immune epitope mapping in the post-genomic era: lessons for vaccine development.
Technological advances have allowed for the creation of ever more complete maps of targets of immune responses in infectious pathogens. The evidence accumulating from such recent studies points to a broader range of targets recognized than previously expected, in terms of both numbers and characteristics of the targeted antigens. Also, multiple studies report a substantial variation in the targets recognized in different human individuals. These findings are not in conflict with the concept of immunodominance, because there are still only a few targets recognized compared with the multitude of potential targets available in a complex pathogen. However, they raise the question if vaccines, which try to emulate protective natural immune responses, should elicit an equally broad range of responses to efficiently convey protection.
Sette
Alessandro
A
La Jolla Institute for Allergy and Immunology, Division of Vaccine Discovery, 9420 Athena Circle, La Jolla, CA 92037, USA. alex@liai.org
Peters
Bjoern
B
D000818:Animals; D018604:Epitope Mapping; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D014612:Vaccines / Q000138:chemical synthesis* / Q000276:immunology*
D000939:Epitopes; D014612:Vaccines